Sugi Predict

Sugi Predict / Compounds / SCHEMBL2845787

SCHEMBL2845787

SCHEMBL2845787

C[C@H](Nc1nc2ccc(Oc3ccnc(-c4cccnc4)n3)cc2s1)C1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 11/20 0.48
▸ RAB9A P51151 4/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ SCD O00767 1/20 0.40
▸ CD274 Q9NZQ7 1/20 0.39
▸ PKM P14618 1/20 0.38
▸ PIK3CG P48736 2/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ PI4KA P42356 2/20 0.38
▸ PI4KB Q9UBF8 2/20 0.38
▸ PDGFRB P09619 2/20 0.38
▸ KIT P10721 2/20 0.38
▸ PDGFRA P16234 2/20 0.38
▸ FLT3 P36888 2/20 0.38
▸ PIP5K1C O60331 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2845793 1.00 CSF1R (0.48) CSF1RRAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2842831 0.90 CSF1R (0.48) CSF1RRAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2842840 0.90 CSF1R (0.48) CSF1RRAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2842986 0.88 CSF1R (0.44) CSF1RRAB9ANPC1MAPTPKM
SCHEMBL2842980 0.88 CSF1R (0.44) CSF1RRAB9ANPC1MAPTPKM
SCHEMBL3882309 0.87 CSF1R (0.49) CSF1RRAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2677341 0.87 CSF1R (0.49) CSF1RRAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2843107 0.86 CSF1R (0.39) CSF1RRAB9ANPC1MAPTPKM
SCHEMBL2843106 0.86 CSF1R (0.39) CSF1RRAB9ANPC1MAPTPKM
SCHEMBL2846300 0.83 CSF1R (0.46) CSF1RRAB9ANPC1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2152700-B1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2013-12-11 — — EP claimed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US claimed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US claimed
EP-2152700-B1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2013-12-11 — — EP disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US disclosed
WO-2008144062-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2008-11-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 CSF1R 1/4885RAB9A 1826/4885NPC1 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.